A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Clinical trial NCT01100502 · COMPLETED

Trial details

NCT number: NCT01100502
Sponsor: Seagen Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Disease, Hodgkin

Start date: 2010-04-30
Primary completion: 2014-08-31
Enrollment: 329

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.